Eldecalcitol |
| Catalog No.GC35971 |
L'eldécalcitol (ED-71) est un analogue de la vitamine D3 actif par voie orale, inhibe la résorption osseuse et augmente la densité minérale osseuse.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 104121-92-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Eldecalcitol (ED-71) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density. IC50 value:Target: Vd analogEldecalcitol (ED-71) is more efficacious than alfacalcidol in preventing vertebral and wrist fractures in osteoporotic patients with vitamin D sufficiency, with a safety profile similar to alfacalcidol.
[1]. Matsumoto T.Osteoporosis Treatment by a New Active Vitamin D3 Compound, Eldecalcitol, in Japan.Curr Osteoporos Rep. 2012 Aug 24. [2]. Shiraki M, et al. Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels.Curr Med Res Opin. 2012 Aug 23. [3]. Matsumoto T, Endo I.Eldecalcitol for the treatment of osteoporosis.Drugs Today (Barc). 2012 Mar;48(3):189-96. [4]. Sakai S, et al.Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.Bone. 2012 May;50(5):1054-63. Epub 2012 Feb 17. [5]. Sanford M, McCormack PL.Spotlight on eldecalcitol in osteoporosis.Drugs Aging. 2012 Jan 1;29(1):69-71.
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *